Latest stories on INKT
MiNK outlines 90-patient randomized Phase II ARDS trial with initial data expected in 2H 2026
Seeking Alpha58 · neutralproduct/pr
MiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
MiNK Therapeutics GAAP EPS of -$0.57 beats by $0.20
Seeking Alpha58 · neutralearnings